San Francisco, CANCT06778863Now EnrollingIRB Ready

Advanced Solid Tumor Clinical Trial in San Francisco, CA

Access cutting-edge advanced solid tumor treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by Clasp Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions…

Expert Care in San Francisco

Access advanced solid tumor specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced solid tumor treatment provided free

Apply for This San Francisco Location

Check if you qualify for this advanced solid tumor clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This Advanced Solid Tumor Study in San Francisco

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

Sponsor: Clasp Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Patients must be at least 18 years of age at the time of signing the informed consent.
Patients must be willing and able to provide written informed consent
Patients must have locally advanced or metastatic solid tumors that have progressed after standard of care therapy or for which no standard therapy exists
Tumors must harbor a TP53 R175H variant mutation confirmed by an accredited laboratory-based test
Patients must be HLA-A\*02:01 positive by central assay
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at the time of enrollment
Adequate hematological, renal and hepatic function
Per Investigator judgement, patient is willing and able to complete study visits and/or procedures per the protocol and comply with study requirements for study participation Key

Exclusion Criteria

Patients with Li-Fraumeni syndrome or other known germline p53 R175H mutation
Patients who have received other p53 R175H-directed therapies
Patients who have not fully recovered from adverse events due to previous anticancer therapies
Patients with active infection requiring systemic antimicrobial therapy
Any other primary malignancy within the 2 years prior to enrollment (except for non- melanoma skin cancer, carcinoma in situ (eg, cervix, bladder, breast) or prostate cancer in remission.
Known active central nervous system metastases and/or carcinomatous meningitis

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT06778863) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Solid Tumor Treatment Options in San Francisco, CA

If you're searching for advanced solid tumor treatment options in San Francisco, CA, this clinical trial (NCT06778863) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumor specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced solid tumor clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in San Francisco, CA

See all advanced solid tumors clinical trials recruiting in San Francisco — not just this study.

Browse Advanced Solid Tumors Trials in San Francisco →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA